Skopos Bio Raises AUD $12 Million to Advance Radioactive Cancer Therapy

Reaching cancer cells that conventional drugs cannot touch has historically required accepting damage to the healthy tissue surrounding them. Skopos Bio is building a class of radioactive particles designed to deliver radiation directly to tumor cells while minimizing exactly that collateral damage.

Skopos Bio, a Melbourne-based precision oncology startup, raised an AUD $12 million seed round, roughly USD $8.4 million, backed by Andrew Forrest's Tenmile, John Wylie's Tin Alley Ventures, and Yosemite, the venture firm headed by Reed Jobs. The company was formed in 2024 by Professor Michael Hofman, Associate Professor Mohammad Haskali, and Associate Professor Luc Furic, who spun the venture out of the Peter MacCallum Cancer Centre. Skopos Bio is developing radiopharmaceuticals, radioactive particles designed to target cancer cells that were previously reachable only by conventional drugs, aiming to cover a broader range of cancers while minimizing damage to surrounding healthy tissue.

Why a Hospital Spinout Has a Different Starting Point Than a Typical Biotech

Spinning a company directly out of a specialized cancer research center, rather than licensing technology after the fact or building from an academic lab with a broader mandate, means Skopos Bio's founding scientists were already embedded in the clinical and research infrastructure most relevant to the problem they are solving. A founding team of three specialists, spanning nuclear medicine, radiochemistry and cancer biology, drawn directly from Peter MacCallum's own research staff gives the company a tighter alignment between its science and the clinical realities of how radiopharmaceuticals actually get used than a team assembled after the fact typically has.

Why High-Profile Individual Backers Chose a Seed-Stage Biotech

A seed round backed by investors as recognizable as Andrew Forrest, John Wylie and Reed Jobs, rather than a traditional biotech-focused venture fund leading the round, suggests Skopos Bio's pitch resonated with investors whose capital often follows conviction in a founding team and a scientific thesis as much as a traditional biotech fund's narrower diligence framework. That kind of backer roster can also signal access to capital and networks beyond the check itself, particularly useful for an early-stage biotech that will likely need several additional rounds before any therapy reaches commercial approval.

What This Means for Founders

For founders building biotech companies spun directly out of hospital or research-center infrastructure, Skopos Bio's seed round is a useful reminder that founding teams embedded in the clinical setting where their technology will eventually be used often have an easier time articulating a credible development path to investors than teams working at more of a remove from clinical practice. Founders in radiopharmaceuticals or adjacent precision-oncology categories should also note that this seed round, while modest by later-stage biotech standards, came from investors known for backing conviction over consensus, a dynamic worth understanding when deciding which kind of early investor to prioritize, and that a syndicate of individually recognizable backers rather than a single institutional lead can sometimes mean slower consensus on follow-on decisions down the line.

Browse the biotech investor directory for more active funds in precision oncology and radiopharmaceuticals, read the baseline mechanics of a seed round if the term is new, or explore active capital on AngelLinx @ angellinx.ai/register.

AngelLinx Intelligence | angellinx.ai